Intracellular delivery of the p38 mitogen-activated protein kinase Inhibitor SB202190 [4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole] in renal tubular Cells: a novel strategy to treat renal fibrosis

Prakash, J.; Sandovici, M.; Saluja, V.; Lacombe, M.; Schaapveld, R.Q.J.; de Borst, M.H.; van Goor, H.; Henning, R.H.; Proost, J.H.; Moolenaar, F.; Keri, G.; Meijer, D.F.K.; Poelstra, K.; Kok, R.J.

Intracellular delivery of the p38 mitogen-activated protein kinase Inhibitor SB202190 [4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole] in renal tubular Cells: a novel strategy to treat renal fibrosis

DSpace/Manakin Repository

Intracellular delivery of the p38 mitogen-activated protein kinase Inhibitor SB202190 [4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole] in renal tubular Cells: a novel strategy to treat renal fibrosis

Prakash, J.; Sandovici, M.; Saluja, V.; Lacombe, M.; Schaapveld, R.Q.J.; de Borst, M.H.; van Goor, H.; Henning, R.H.; Proost, J.H.; Moolenaar, F.; Keri, G.; Meijer, D.F.K.; Poelstra, K.; Kok, R.J.

(2006) Journal of Pharmacology and Experimental Therapeutics, volume 319, pp. 1 - 12

(Article)

Download/Full Text

Open Access version via Utrecht University Repository

Publisher version

Keywords: Medical technology, Farmacie(FARM), Biomedische technologie en medicijnen, Pharmacology

ISSN: 0022-3565

Publisher: American Society for Pharmacology and Experimental Therapy

(Peer reviewed)

See more statistics about this item